ABSTRACT
Gemcitabine (Gem) is currently used as the first-line therapy for liver and pancreatic cancer but has limited efficacy in most cases. Dexamethasone (Dex) have been applied as a chemoprotectant and chemosensitizer in cancer chemotherapy. This study further explored the potential of combination of Gem and Dex and tested the hypothesis that glucocorticoid receptor signaling is essential for the synergistic antitumor activity. In the HepG2 and AsPC-1 xenograft models, the combination treatment showed a significantly synergistic antitumor activity. Immunohistochemistry of post-treatment tumors showed a significant decrease in proliferation and angiogenesis as compared to either of the treatments alone. Dex alone and the combination with Gem inhibited the expression of glucocorticoid receptor. The combination of Dex and Gem showed synergistic cytotoxicity in cell lines in vitro. The antiproliferative synergism is prevented by used glucocorticoid receptor (GR) small interfering RNA, demonstrating that the glucocorticoid receptor is required for the antiproliferative synergism of Gem and Dex. The inhibition of glucocorticoid receptor signaling pathway and induction of apoptosis via activation of caspases 3, 8 and 9, PARP, contributed to the synergistic effect of this combination therapy. These results demonstrate that Dex could potentiate the antitumor efficacy of Gem. The synergistic antitumor activity of the combination of Dex and Gem was through glucocorticoid receptor signaling. Taken together, a combination of Dex and Gem shows a significant synergistic antitumor activity and lesser toxicity both in vitro and in vivo and could be a combination chemotherapy for the treatment of highly expression of glucocorticoid receptor patients.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Carcinoma, Hepatocellular/drug therapy , Drug Synergism , Gene Expression Regulation, Neoplastic/drug effects , Liver Neoplasms/pathology , Pancreatic Neoplasms/drug therapy , Receptors, Glucocorticoid/metabolism , Animals , Apoptosis , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cell Proliferation , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Dexamethasone/administration & dosage , Female , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/metabolism , Mice , Mice, Inbred BALB C , Mice, Nude , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Tumor Cells, Cultured , Xenograft Model Antitumor Assays , GemcitabineABSTRACT
In this article, we analyze the clinical characteristics of five kinds of traditional Chinese medicine injections in treating heart failure based on Meta-analysis. A total of 24 Meta-analysis papers were included, which involved Shenfu Injection, Shenmai Injection, Shengmai Injection, Danhong Injection and Huangqi Injection. The numbers of literatures of Shenfu Injection, Shenmai Injection and Shengmai Injection are high than the other two injections. The efficiencies of these injections combined with Western medicine are higher than the Western medicine used alone. They can improve 6 minute walk test result, ejection fraction, the level of brain peptide sodium and so on. Shenfu Injection can also improve the living quality of patients' life, heart rate and other indicators. Shenfu Injection can be used for patients with Yin deficiency, while Shenmai Injection can be used for patients with Yin deficiency and Shengmai Injection can be used for patients with Qi and Yin deficiency. From this information, we can see that Western medicine combined with traditional Chinese medicine injections can significantly improve the clinical efficiency. These injections need to be used according to patients' symptom. In the present, as the quality of clinical research literature of traditional Chinese medicine injections is low, the efficiency and safety evaluation of Chinese medicine injections still requires higher level of clinical evidence.
Subject(s)
Drugs, Chinese Herbal/therapeutic use , Heart Failure/drug therapy , Humans , Injections , Medicine, Chinese Traditional , Yin DeficiencyABSTRACT
OBJECTIVE: To establish fingerprint of Cortex Fraxini and provide reference for quality evaluation of Cortex Fraxini. METHOD: Chromatographic experiments were performed on Agilent Extend C18 column (4.6 mm x 250 mm, 5 microm), eluted with methanol and water, containing 0.4% acetic acid as the mobile phases in gradient elution. The detection wavelength was 0-60 min, 340 nm; 6-74 min, 254 nm; 74-75 min, 340 nm, and the flow rate was 1.0 mL x min(-1). Forty samples in four varieties of Cortex Fraxini were detected to establish fingerprints, respectively. RESULT: Every parameter of the method validation complied with related rules and regulations. There were 15 common peaks in the fingerprint of 10 Fraxinus rhynchophylla samples, eleven common peaks in the fingerprint of 10 F. chinensis var. acuminata. samples, and in the fingerprint of 10 F. chinensis samples. Nineteen common peaks in the fingerprint of 10 F. stylosa samples. There were 5 common peaks in the fingerprints of 40 Cortex Fraxini samples. The similarity factors of the 10 samples of every species were all more than 0.96 compared with the control fingerprint. The similarity of the 40 Cortex Fraxini samples was more than 0.90. Four effective constituents and one unknown constituent were found in 40 samples. CONCLUSION: The fingerprints of F. rhynchophylla bark, F. chinensis bark, F. chinensis var. acuminata bark, F. stylosa bark and Cortex Fraxini were established. The methodological evaluation showed that the results were in accord with the technology requirements of chromatography fingerprint, and it laid a good foundation for quality control of Cortex Fraxini.
